Skip to main content

Table 1 Baseline characteristics of the patients (N = 11)

From: A phase II, open-label clinical trial on the combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary disease

Age, years71.3 (4.8), 64–78
Sex, male/female (number)10/1
BMI, kg/m217.4 (1.9), 13.9–20.9
Cigarette smoking, pack years54.6 (24.7), 24.5–98
GOLD, III/IV, number6/5
Pulmonary function test
 FEV1, L0.82 (0.25), 0.41–1.29
 %FEV1, % predicted32.2 (9.4), 16.8–48.2
 FEV1/FVC, %34.3 (6.6), 22.9–46.0
 VC, L2.47 (0.57), 1.83–3.39
 %VC, %78.3 (15.7), 55.6–100.5
Incremental work rate exercise testing
 At peak exercise 
 Dyspnea, Borg scale5.8 (1.2), 4–7
 \( V_{{{\text{O}}_{2} }}^{{\prime }} \), mL/min/kg10.6 (2.6), 6.9–14.1
SGRQ
 Total score55.6 (17.7), 26.8–79.9
 Symptoms score67.5 (20.6), 19.1–92.0
 Activity score70.1 (13.1), 54.4–92.5
 Impacts score40.3 (22.4), 4.9–73.4
Medications (number)
 LAMA11
 LABA9
 ICS6
 Triple inhalation therapy5
 Methylxanthines0
  1. Data are presented as mean (SD) and as the minimum and maximum values, unless otherwise stated
  2. BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease, ICS inhaled corticosteroids, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, SGRQ St. George Respiratory Questionnaire; Triple inhalation; a combination of LAMA, LABA, and ICS, VC vital capacity, \( V_{{O_{2} }}^{\prime } \) oxygen uptake
  3. Medications are presented separately